Eton Q2 revenue $37.6M (+99% YoY), raises FY26 guidance to >$145M

Eton Pharmaceuticals, Inc.

Q2 net revenue $37.6M vs $18.9M YoY; GAAP EPS $0.35, non-GAAP $0.43.
Adjusted EBITDA $16.2M (43% margin) vs $3.1M (16%) YoY; EBITDA $14.1M.
FY26 revenue guidance raised to >$145M (from >$120M); Adjusted EBITDA margin ≥35% (from ≥30%).
HEMANGEOL relaunch May 1; ~95% patient conversion by end of June; ASN-001 licensed.
Acquired U.S. rights to IMPAVIDO (launch Sept 2026); KHINDIVI PAS submitted for expanded indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.